JP2014518882A5 - - Google Patents

Download PDF

Info

Publication number
JP2014518882A5
JP2014518882A5 JP2014512183A JP2014512183A JP2014518882A5 JP 2014518882 A5 JP2014518882 A5 JP 2014518882A5 JP 2014512183 A JP2014512183 A JP 2014512183A JP 2014512183 A JP2014512183 A JP 2014512183A JP 2014518882 A5 JP2014518882 A5 JP 2014518882A5
Authority
JP
Japan
Prior art keywords
alkyl
independently selected
compound
alkoxy
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014512183A
Other languages
English (en)
Japanese (ja)
Other versions
JP6198721B2 (ja
JP2014518882A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/039835 external-priority patent/WO2012166716A2/en
Publication of JP2014518882A publication Critical patent/JP2014518882A/ja
Publication of JP2014518882A5 publication Critical patent/JP2014518882A5/ja
Application granted granted Critical
Publication of JP6198721B2 publication Critical patent/JP6198721B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014512183A 2011-05-27 2012-05-29 Hcv感染症を治療するのに有用な置換されたアリファン、シクロファン、ヘテラファン、ヘテロファン、ヘテロ−ヘテラファンおよびメタロセン Expired - Fee Related JP6198721B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161490881P 2011-05-27 2011-05-27
US61/490,881 2011-05-27
US201161504905P 2011-07-06 2011-07-06
US61/504,905 2011-07-06
US201161567216P 2011-12-06 2011-12-06
US61/567,216 2011-12-06
PCT/US2012/039835 WO2012166716A2 (en) 2011-05-27 2012-05-29 Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017044853A Division JP2017101086A (ja) 2011-05-27 2017-03-09 Hcv感染症を治療するのに有用な置換されたアリファン、シクロファン、ヘテラファン、ヘテロファン、ヘテロ−ヘテラファンおよびメタロセン

Publications (3)

Publication Number Publication Date
JP2014518882A JP2014518882A (ja) 2014-08-07
JP2014518882A5 true JP2014518882A5 (US07714131-20100511-C00001.png) 2015-07-09
JP6198721B2 JP6198721B2 (ja) 2017-09-20

Family

ID=47219638

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014512183A Expired - Fee Related JP6198721B2 (ja) 2011-05-27 2012-05-29 Hcv感染症を治療するのに有用な置換されたアリファン、シクロファン、ヘテラファン、ヘテロファン、ヘテロ−ヘテラファンおよびメタロセン
JP2017044853A Pending JP2017101086A (ja) 2011-05-27 2017-03-09 Hcv感染症を治療するのに有用な置換されたアリファン、シクロファン、ヘテラファン、ヘテロファン、ヘテロ−ヘテラファンおよびメタロセン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017044853A Pending JP2017101086A (ja) 2011-05-27 2017-03-09 Hcv感染症を治療するのに有用な置換されたアリファン、シクロファン、ヘテラファン、ヘテロファン、ヘテロ−ヘテラファンおよびメタロセン

Country Status (25)

Country Link
US (8) US8809313B2 (US07714131-20100511-C00001.png)
EP (2) EP3059241B1 (US07714131-20100511-C00001.png)
JP (2) JP6198721B2 (US07714131-20100511-C00001.png)
KR (1) KR101931311B1 (US07714131-20100511-C00001.png)
CN (2) CN105801467A (US07714131-20100511-C00001.png)
AP (1) AP2013007263A0 (US07714131-20100511-C00001.png)
AU (2) AU2012262338B2 (US07714131-20100511-C00001.png)
BR (1) BR112013030045A2 (US07714131-20100511-C00001.png)
CA (1) CA2837481A1 (US07714131-20100511-C00001.png)
CY (1) CY1118111T1 (US07714131-20100511-C00001.png)
EA (2) EA201791776A1 (US07714131-20100511-C00001.png)
ES (1) ES2584418T3 (US07714131-20100511-C00001.png)
HK (1) HK1196559A1 (US07714131-20100511-C00001.png)
HR (1) HRP20160863T1 (US07714131-20100511-C00001.png)
HU (1) HUE029326T2 (US07714131-20100511-C00001.png)
IL (3) IL229165A (US07714131-20100511-C00001.png)
LT (1) LT2714036T (US07714131-20100511-C00001.png)
MX (2) MX357867B (US07714131-20100511-C00001.png)
PL (1) PL2714036T3 (US07714131-20100511-C00001.png)
PT (1) PT2714036T (US07714131-20100511-C00001.png)
RS (1) RS55123B1 (US07714131-20100511-C00001.png)
SG (1) SG194681A1 (US07714131-20100511-C00001.png)
SI (1) SI2714036T1 (US07714131-20100511-C00001.png)
SM (1) SMT201600325B (US07714131-20100511-C00001.png)
WO (1) WO2012166716A2 (US07714131-20100511-C00001.png)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012533569A (ja) 2009-07-16 2012-12-27 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体
MX2012010918A (es) 2010-03-24 2013-01-18 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones por flavivirus.
US8859595B2 (en) 2010-08-26 2014-10-14 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis C virus
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AP2013007263A0 (en) 2011-05-27 2013-11-30 Achillion Pharmaceuticals Inc Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenesuseful for treating HCV infections
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2015148006A (ru) 2013-04-12 2017-05-18 Ачиллион Фармасютикалз, Инк. Дейтерированные нуклеозидные пролекарства, применимые для лечения hcv
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2015026454A1 (en) * 2013-07-17 2015-02-26 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis c virus
US9717712B2 (en) * 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
CN105517574B (zh) * 2013-07-09 2019-01-18 百时美施贵宝公司 丙型肝炎病毒抑制剂的组合产品
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
WO2016020288A1 (en) 2014-08-04 2016-02-11 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
WO2016054240A1 (en) 2014-09-30 2016-04-07 Sean Dalziel Fixed dose combinations for the treatment of viral diseases
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) * 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
CN108349907B (zh) * 2015-11-06 2021-08-31 江苏豪森药业集团有限公司 1,4(1,4)-二苯杂环六蕃-12,43-二基衍生物及其制备方法与应用
WO2017076194A1 (zh) * 2015-11-06 2017-05-11 江苏豪森药业集团有限公司 具有抑制hcv活性的化合物及其制备方法和应用
CN106083829B (zh) * 2016-01-12 2019-01-22 深圳市塔吉瑞生物医药有限公司 一种丙型肝炎病毒抑制剂、药物组合物及其应用
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3454856A4 (en) 2016-05-10 2019-12-25 C4 Therapeutics, Inc. HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2018064585A1 (en) * 2016-09-29 2018-04-05 Janssen Pharmaceuticals, Inc. Odalasvir polymorphs and methods of manufacture thereof
ES2933513T3 (es) 2017-03-01 2023-02-09 Achillion Pharmaceuticals Inc Compuestos macrocíclicos para el tratamiento de trastornos médicos
EP3985002A1 (en) 2017-03-01 2022-04-20 Achillion Pharmaceuticals, Inc. Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3847174A4 (en) 2018-09-06 2022-06-15 Achillion Pharmaceuticals, Inc. MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
MX2021003425A (es) 2018-09-25 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
TW202106677A (zh) * 2019-04-25 2021-02-16 美商貝達醫藥公司 用於治療c型肝炎病毒感染之ns5a的二胺甲酸酯抑制劑
EP4076657A1 (en) 2019-12-20 2022-10-26 Nuevolution A/S Compounds active towards nuclear receptors
CA3174176A1 (en) 2020-03-31 2021-10-07 Sanne Schroder Glad Compounds active towards nuclear receptors
MX2022012260A (es) 2020-03-31 2022-11-30 Nuevolution As Compuestos activos frente a receptores nucleares.
CN115181117B (zh) * 2022-08-08 2024-05-17 中国医学科学院医学生物学研究所 一种s构型手性分子化合物及其制备方法和作为疫苗佐剂的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US6599887B2 (en) 1988-07-07 2003-07-29 Chimerix, Inc. Methods of treating viral infections using antiviral liponucleotides
DE4010531A1 (de) * 1990-04-02 1991-10-10 Thomae Gmbh Dr K Cyclophane, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JP3889708B2 (ja) * 2000-11-20 2007-03-07 ブリストル−マイヤーズ スクイブ カンパニー C型肝炎トリペプチド阻害剤
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
EP1879575A2 (en) 2005-05-09 2008-01-23 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
EP2012799B1 (en) 2006-05-03 2016-08-24 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
KR101512477B1 (ko) 2006-07-13 2015-04-15 아칠리온 파르마세우티칼스 인코포레이티드 바이러스 복제 억제제로서 사용되는 4-아미노-4-옥소부타노일 펩티드
CN101506223B (zh) * 2006-07-13 2013-05-22 艾其林医药公司 作为病毒复制抑制剂的4-氨基-4-氧代丁酰基肽
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100158862A1 (en) 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN101801964A (zh) 2007-05-22 2010-08-11 艾其林医药公司 杂芳基取代的噻唑及其作为抗病毒剂的用途
JP2010540549A (ja) * 2007-09-24 2010-12-24 アキリオン ファーマシューティカルズ,インコーポレーテッド ウイルス複製阻害剤としての尿素含有ペプチド
CA2743912A1 (en) 2008-11-20 2010-05-27 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus
PL2364309T3 (pl) 2008-12-10 2015-03-31 Achillion Pharmaceuticals Inc Nowe peptydy 4-amino-4-oksobutanoilowe jako inhibitory wirusowej replikacji
EA021794B1 (ru) 2008-12-10 2015-09-30 Ачиллион Фармасьютикалз, Инк. Циклические аналоги 4-амино-4-оксобутаноил пептидов, ингибиторы репликации вирусов
WO2010091413A1 (en) * 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
ME02418B (me) 2009-03-27 2016-09-20 Merck Sharp & Dohme Inhibitori replikacije virusa hepatitisa c
TWI476190B (zh) * 2009-03-30 2015-03-11 必治妥美雅史谷比公司 C型肝炎病毒抑制劑
AP3622A (en) 2009-05-13 2016-03-02 Gilead Sciences Inc Antiviral compounds
EP2475256A4 (en) 2009-09-11 2013-06-05 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
WO2011050146A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Chemical compounds
JP2013518062A (ja) 2010-01-28 2013-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング C型肝炎阻害化合物
AP2013007263A0 (en) 2011-05-27 2013-11-30 Achillion Pharmaceuticals Inc Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenesuseful for treating HCV infections

Similar Documents

Publication Publication Date Title
JP2014518882A5 (US07714131-20100511-C00001.png)
JP2017526726A5 (US07714131-20100511-C00001.png)
JP2017528524A5 (US07714131-20100511-C00001.png)
JP2012523457A5 (US07714131-20100511-C00001.png)
JP2016506962A5 (US07714131-20100511-C00001.png)
JP2020500182A5 (US07714131-20100511-C00001.png)
JP2015501833A5 (US07714131-20100511-C00001.png)
JP2017537949A5 (US07714131-20100511-C00001.png)
JP2015523383A5 (US07714131-20100511-C00001.png)
RU2015118647A (ru) Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr
HRP20161786T1 (hr) Pirolidinil urea, pirolidinil tiourea i pirolidinil gvanidin spojevi kao inhibitori trka kinaze
JP2017528467A5 (US07714131-20100511-C00001.png)
JP2016506960A5 (US07714131-20100511-C00001.png)
JP2013510120A5 (US07714131-20100511-C00001.png)
JP2014511892A5 (US07714131-20100511-C00001.png)
JP2013507425A5 (US07714131-20100511-C00001.png)
JP2012528166A5 (US07714131-20100511-C00001.png)
JP2016516043A5 (US07714131-20100511-C00001.png)
JP2016506961A5 (US07714131-20100511-C00001.png)
JP2015514806A5 (US07714131-20100511-C00001.png)
JP2009504764A5 (US07714131-20100511-C00001.png)
JP2014521688A5 (US07714131-20100511-C00001.png)
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
JP2011509309A5 (US07714131-20100511-C00001.png)
RU2013136895A (ru) Новое бициклическое соединение или его соль